Financial Performance - The company achieved operating revenue of RMB 4,672,269 thousand, a year-on-year increase of 27.51%[43] - Net profit attributable to shareholders reached RMB 269,807 thousand, reflecting a growth of 38.80% compared to the previous year[43] - The company's net profit for the reporting period was RMB 26,173 thousand, a decrease of 13.82% compared to the same period last year, primarily due to severe market competition and insufficient demand leading to price declines[59] - The total profit for the period was RMB 331,945,812.26, representing a 41.06% increase year-on-year, showcasing improved profitability despite market challenges[82] - The total revenue for the first half of 2023 reached RMB 4,672,269,049.13, an increase from RMB 3,664,294,993.33 in the same period of 2022, representing a growth of approximately 27.5%[176] - The net profit for the first half of 2023 was RMB 275,680,432.27, compared to RMB 198,503,873.29 in the previous year, indicating a year-over-year increase of about 38.9%[176] - The operating profit for the first half of 2023 was RMB 333,956,283.28, up from RMB 237,764,708.38 in the same period last year, reflecting a growth of approximately 40.4%[176] - The total profit for the first half of 2023 was RMB 389,680,562.47, compared to RMB 155,353,236.44 in the same period of 2022, marking an increase of approximately 150%[189] Assets and Liabilities - The company reported a total long-term loan balance of RMB 804,985,266.90 at the end of the period, an increase from RMB 545,655,801.48 at the beginning of the year, representing a growth of approximately 47.3%[5] - The company’s total debt to capital ratio was 30.69% as of June 30, 2023[58] - The company's debt-to-asset ratio stood at 43.66%[88] - The total liabilities decreased to RMB 3,027,014,336.22 as of June 30, 2023, from RMB 3,401,905,893.46 at the end of 2022, a reduction of about 11%[174] - The total equity increased to RMB 3,862,924,360.67 as of June 30, 2023, compared to RMB 3,584,735,295.66 at the end of 2022, showing an increase of approximately 7.8%[174] Cash Flow and Liquidity - The company's cash and cash equivalents amounted to RMB 979,173,294.29, accounting for 12.13% of total assets[50] - The company's cash and cash equivalents at the end of the period amounted to RMB 979,173,294.29, a decrease of 15.5% from RMB 1,158,741,565.90 at the beginning of the year[171] - The total amount of restricted cash at the end of the period was RMB 124,873,547.56, down from RMB 147,977,218.39 at the beginning of the year, representing a decrease of 15.6%[171] - The company reported a significant decrease of 143.28% in the net increase of cash and cash equivalents, totaling RMB -156,464,600.78, highlighting liquidity challenges[83] Research and Development - Research and development expenses increased significantly as the company continued to enhance its technological innovation efforts[53] - The company’s research and development expenses in the first half of 2023 amounted to RMB 186,037,994.31, up from RMB 125,880,884.19 in the previous year, reflecting a growth of approximately 48%[189] - Research and development expenses increased by 39.72% to RMB 235,529,909.24 compared to the previous year, reflecting the company's commitment to innovation[82] - The company has established a comprehensive new drug research and development system and collaborates with over 50 domestic and international research institutions[91] Employee and Corporate Governance - The company’s total number of employees is 6,839, with 1,688 holding a university degree or higher[25] - The total number of employees as of June 30, 2023, was 6,839, with 3,864 in production roles and 904 in sales[41] - The company confirmed compliance with corporate governance codes and regulations as of June 30, 2023[169] - The company has appointed four independent non-executive directors, including one with financial management expertise, in accordance with listing rules[170] Environmental Compliance - The company has not faced any administrative penalties due to environmental issues during the reporting period, indicating compliance with environmental regulations[65] - The company has built three wastewater treatment facilities with a total capacity of 12,000 tons per day to ensure compliance with discharge standards[97] - The company has maintained its environmental management system since 1999, achieving multiple certifications from 2000 to 2022[102] - The company implemented a new RTO device with a capacity of 30,000 m³/h in 2022, which was officially put into operation in January 2023 to improve environmental conditions[133] Market and Product Development - The company launched 7 new products in the first half of the year, including 5 formulations and 1 active pharmaceutical ingredient, indicating a focus on product development[76] - The company has established long-term strategic partnerships with over 200 multinational corporations, including Bayer and GlaxoSmithKline, and is recognized as one of the top 15 enterprises in China to implement an internationalization strategy in pharmaceuticals[60] - The revenue from tablets, injections, and capsules was approximately RMB 2.09 billion, with a growth rate of 28.72%[85] - The revenue from direct sales was approximately RMB 1.88 billion, with a growth rate of 29.54%[85] - The revenue from the Americas region increased by 23.93%, reaching approximately RMB 405 million[85] Taxation - The company’s tax rate for its subsidiary, recognized as a high-tech enterprise, is 15% for the first half of 2023[13] - The effective corporate income tax rate for the company is currently 15% due to its recognition as a high-tech enterprise, which is under re-evaluation for 2023[185] - The company has subsidiaries benefiting from a 15% corporate income tax rate, including Shandong Xinhua Pharmaceutical Chemical Design Co., Ltd., recognized as a high-tech enterprise[186] Financial Management - The company reported a financial expense of RMB 1,688,843.56 in the first half of 2023, a decrease from RMB 16,651,235.73 in the previous year, indicating improved financial management[189] - The company’s other income for the first half of 2023 was RMB 11,102,958.72, down from RMB 15,323,110.21 in the same period of 2022, showing a decline of about 27%[189] Shareholder Matters - The board of directors has recommended not to distribute dividends for the first half of 2023 and will not increase capital from reserves[106] - The company has not engaged in any asset management or leasing arrangements with other companies during the reporting period[108] - There were no significant asset acquisitions or disposals during the reporting period[107]

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 企业负责人：贺同庆 主管会计工作的负责人 ：侯宁 会计机构负责人：何晓洪 | 上市公司名称：山东新华制药股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关 联关系 | | 上市公司核算的会计科目 2023年初占用资金余额 | 2023年半年度占用累计发 生金额（不含利息） | 2023年半年度占 用资金的利息 | 2023年半年度偿还累 计发生金额 | 2023年6月末占用资金余额 | 占用形成原因 | 占用性质 | | 现大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 总计 | | | | | | | | | | | | 其它关联资金 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,672,269,049.13, representing a 27.51% increase compared to RMB 3,664,294,993.33 for the same period in 2022[5] - Total profit for the same period was RMB 331,945,812.26, up 41.06% from RMB 235,316,728.47 in the previous year[5] - Net profit attributable to shareholders was RMB 269,807,157.85, reflecting a 38.80% increase from RMB 194,389,556.12 in the prior year[5] - Basic earnings per share increased to RMB 0.40, a rise of 33.33% compared to RMB 0.30 in the same period last year[5] - Operating revenue for the six months ended June 30, 2023, reached RMB 4,672,269,049.13, an increase of 27.51% compared to the same period in 2022[24] - The company's net profit for the six months ended June 30, 2023, was RMB 275,680,432.27, representing a 38.88% increase compared to the same period in 2022[24] - The total profit for the six months ended June 30, 2023, was RMB 331,945,812.26, a 41.06% increase year-on-year, driven by expanded sales scale and improved management efficiency[24] - The company reported a net profit margin for the reporting period of approximately 5.89%, compared to 5.42% in the previous year[5] Assets and Liabilities - The company's total assets as of June 30, 2023, were RMB 8,075,584,581.73, a decrease of 2.29% from RMB 8,265,131,332.13 at the end of 2022[5] - Total liabilities decreased by 9.96% to RMB 3,525,405,717.37 from RMB 3,915,226,169.32 at the end of 2022[5] - The company's total debt amounted to RMB 1,329,244,000, with cash and cash equivalents of RMB 979,173,000[30] - The asset-liability ratio stood at 43.66%, reflecting the company's financial stability[30] - Current assets totaled RMB 3,235,189,305.38, down from RMB 3,456,959,427.88, indicating a decrease of about 6.41%[46] - The company's cash and cash equivalents decreased to RMB 979,173,294.29 from RMB 1,158,741,565.90, a reduction of approximately 15.5%[46] - Total liabilities as of June 30, 2023, were RMB 3,525,405,717.37, down from RMB 3,915,226,169.32 at the end of 2022, indicating a reduction of approximately 9.9%[53][54] Operational Highlights - Domestic sales of active pharmaceutical ingredients (APIs) grew by 78.49% year-on-year, reflecting the company's strong market position[15] - Sales of industrial formulations increased by 48.66% year-on-year, while formulation processing and export business saw a remarkable growth of 93.97%[15] - The company launched 7 new products in the first half of 2023, including 5 formulation products and 1 active pharmaceutical ingredient[15] - A total of 10 drug production approvals and 6 veterinary drug approvals were obtained, marking a historical high for the company[16] - The company is advancing key projects, with construction completed for 4 projects, including DCB and methyldopa, now moving into equipment installation[15] - The company’s commercial segment achieved rapid growth, focusing on both pharmaceutical and non-pharmaceutical sectors[15] Research and Development - Research and development expenses increased by 39.72% year-on-year, totaling RMB 235,529,909.24, reflecting the company's commitment to technological innovation[24] - The company was granted 22 patents, including 8 invention patents, demonstrating its commitment to innovation[16] Cash Flow and Financial Management - The company reported a significant decrease in net cash flow from operating activities, which was RMB 20,131,070.66, down 89.67% from RMB 194,801,492.76 in the previous year[5] - Financial expenses decreased by 90.75% to RMB 1,341,987.35, attributed to optimized financing structure and increased foreign exchange gains[24] - Short-term borrowings rose by 106.31% to RMB 243,494,933.55, indicating a strategy to optimize the debt structure and reduce financing costs[23] Shareholder Information - As of June 30, 2023, the top shareholder, China Hualu Holdings Group Co., Ltd., held 30.36% of the shares, totaling 204,864,092 shares[8] - Hualu Holdings committed not to reduce its shareholding in the company within six months prior to the pricing benchmark date of the non-public A-share issuance[33] - Hualu Holdings promised to avoid any business or activities that may cause competition or conflict of interest with the company's main business during its control period[33] Compliance and Governance - The company has adhered to corporate governance codes during the reporting period without deviation[42] - The audit committee has reviewed the unaudited interim accounts for the six months ending June 30, 2023, and agreed with the financial accounting principles adopted[43] - The company has maintained compliance with the standards set forth in the "Standard Code" regarding securities trading, confirming no violations during the reporting period[45] Future Outlook - The company aims to obtain 6 new product production approvals, 1 raw material production approval, 2 clinical approvals, and 2 consistency evaluation approvals in the second half of the year[20] - The company plans to enhance market driving force by leveraging the diverse specifications of raw materials and expanding both export and domestic sales[19] - The company is actively expanding its pharmaceutical logistics and brand operations to improve profitability and accelerate growth[19] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[70]

证券代码：000756 证券简称：新华制药 公告编号： 2023-37 山东新华制药股份有限公司 关于获得苯甲酸阿格列汀片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的苯甲酸阿格列汀片（以下简称"该产品"）《药品注册证书》。现将 相关情况公告如下： 一、基本情况 药品名称：苯甲酸阿格列汀片 剂型：片剂 受理号：CYHS2200419国、CYHS2200420国 药品批准文号：国药准字H20234021、国药准字H20234022 证书编号：2023S01252、2023S01253 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。 二、其他相关信息 规格：25mg、12.5mg 药品分类：处方药 注册分类：化学药品4类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 山东新华制药股份有限公司董事会 2023年8月11日 2022年3月，新华制药向国家药 ...

Stock Options Incentive Plans - The company reported a total of 10,692,000 stock options granted under the 2018 A-share stock option incentive plan, with 5,167,800 options vested by the end of the reporting period[4]. - No stock options under the 2018 A-share stock option incentive plan have expired during the reporting period[5]. - The company has not granted stock options exceeding 1% of its total issued share capital to any participant, nor more than 0.1% in any 12-month period[5]. - As of December 31, 2022, there were no unvested stock options remaining for the participants under the 2018 plan[5]. - The company granted 9,035,400 stock options to other employee participants, with 4,339,500 options vested by the end of the reporting period[4]. - The company’s stock options have a waiting period of 24, 36, and 48 months, with specific exercise periods defined[5]. - The company’s stock options are structured to allow 34% to be exercised after 24 months, 33% after 36 months, and the remaining 33% after 48 months[5]. - The stock options under the 2021 A-share stock option incentive plan have a waiting period of 24, 36, and 48 months from the grant date, with 34% exercisable after 24 months[10]. - No stock options under the 2021 A-share stock option incentive plan have expired during the reporting period[10]. - The company has not granted or will grant options exceeding 1% of its total issued share capital to any participant, and no more than 0.1% in any 12-month period[10]. Compensation for Executives - The total compensation for key executives amounts to 3,870,000 RMB, with additional employee participants totaling 19,280,000 RMB, leading to a combined total of 23,150,000 RMB for the reporting period[8]. Company Governance - The company aims to further elaborate on its stock option incentive plan following the disclosure of its 2022 annual report[2]. - The company’s board of directors remains unchanged as of the announcement date, with key executives including the chairman and independent directors listed[11]. Stock Option Grants - The company granted 1,750,000 stock options to certain employee participants on December 26, 2022, with an exercise price of 37.53 RMB per share, and a fair value of 14.67 RMB per share at the grant date[9]. - The company has provided a summary of the stock option changes for the 2021 A-share stock option incentive plan, indicating ongoing management of employee incentives[5].

证券代码：000756 证券简称：新华制药 山东新华制药股份有限公司投资者关系活动记录表 编号：2023-01 投资者关系活动 类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他 参与单位名称及 人员姓名 线上参与公司2022年度网上业绩说明会的全体投资者 时间 2023年04月26日 15:00-16:30 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待人 员姓名 董事长贺同庆先生、董事总经理徐文辉先生、独立董事潘广成先生、董事财务负责 人侯宁先生、董事会秘书曹长求先生、保荐机构代表人白仲发先生 投资者关系活动 主要内容介绍 1.请问公司兽药产能及今年的预计销售金额是多少？请问高端宠物饲料的产 能及预计年度销售金额大概多少？ 公司高纯度鱼油国内零售市场现状及规划 答:公司高密园区主要功能定位为动保相关产品的研发与生产，其中也包括高 端宠物饲料项目，目前高密园区处于起步爬坡阶段。 心脑血管疾病一直都是危害人类健康的重要杀手，如何预防心脑血管疾病一 直是新华研究的重要课题之一。目前新华已经形成了以阿司匹林原料药为主 ...

证券代码：000756 证券简称：新华制药 公告编号：2023-21 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 一、主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|--------------------------------| | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期 增减（%） | | 营业收入（元） | 2,639,665,769.78 | 1,831,254,151.22 | 44.15% | | 归属于上市公司股东的净利润（元） | 151,603,818.36 | 108,503,552.76 | 39.72% | | 归属于上市公司股东的扣除非经常性损益的净 利润（元） | 147,158,093.14 ...

Financial Performance - Operating revenue for Q1 2023 reached RMB 2,639,665,769.78, representing a 44.15% increase compared to RMB 1,831,254,151.22 in Q1 2022[2] - Net profit attributable to shareholders was RMB 151,603,818.36, up 39.72% from RMB 108,503,552.76 in the same period last year[2] - Basic earnings per share increased to RMB 0.23, a rise of 35.29% from RMB 0.17 in Q1 2022[3] - The total comprehensive income for Q1 2023 was RMB 161,720,238.98, compared to RMB 94,819,997.43 in Q1 2022[5] - The company reported a net profit margin of approximately 5.74% for Q1 2023, compared to 5.92% in Q1 2022[4] Cash Flow and Assets - The net cash flow from operating activities showed a significant decline, amounting to (RMB 183,742,803.27), a decrease of 937.28% compared to (RMB 17,713,946.61) in Q1 2022[2] - Total assets as of March 31, 2023, were RMB 7,976,649,915.84, down 3.49% from RMB 8,265,131,332.13 at the end of 2022[3] Equity and Returns - The return on equity (ROE) increased to 3.59%, up 0.52 percentage points from 3.07% in Q1 2022[3] - The total equity attributable to shareholders increased to RMB 4,323,961,931.78, a growth of 4.79% from RMB 4,126,460,390.95 at the end of 2022[3] Research and Development - Research and development expenses for Q1 2023 were RMB 112,119,587.26, reflecting an increase from RMB 78,758,186.08 in Q1 2022[4] Accounting Policy Changes - The company has implemented changes to its accounting policies effective from January 1, 2023, in accordance with the Ministry of Finance's announcement on November 30, 2022[6] - The changes include the treatment of deferred income tax related to assets and liabilities arising from individual transactions, which are not subject to initial recognition exemptions[6] - The board of directors approved the accounting policy changes during the 11th meeting of the 10th board session on April 20, 2023[6]

山 東 新 華 製 藥 股 份 有 限 公 司 Shandong Xinhua Pharmaceutical Company Limited ( H股股份代號：0719 ) ( A股股份代號 : 000756 ) ( H Share Stock Code : 0719 ) ( A Share Stock Code : 000756 ) 2022 Annual Report 年 報 | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------| | | | 目錄 CONTENTS | | 重要提示 | 2 | 公司基本情況簡介 Company Information | | 本公司董事會、監事會及董事、監事、 高級管理人員保證本報告所 ...

2023-18 证券代码：000756 证券简称：新华制药 公告编号： 山东新华制药股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 山东新华制药股份有限公司（以下简称"公司"）已于 2023 年 3 月 27 日在巨潮 资讯网（www.cninfo.com.cn）披露了《2022 年年度报告》及《2022 年年度报告摘要》。 根据《上市公司自律监管指南第 1 号——业务办理》的规定，为便于广大投资者更加 全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 4 月 26 日（星期 三）15:00-16:30 通过"价值在线"（www.ir-online.cn）举办 2022 年度网上业绩说 明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 二、出席人员 出席本次网上业绩说明会的人员有：董事长贺同庆先生，董事、总经理徐文辉先 生，独立董事潘广成先生，董事、财务负责人侯宁先生，董事会秘书曹长求先生，保 荐机构代表人白仲发先生。如存在特殊情况，公司将根据实际情况调整出席人员。 三、会议问 ...